Asprosin response in hypoglycemia is not related to hypoglycemia unawareness but rather to insulin resistance in type 1 diabetes
Autoři:
Jan Benedikt Groener aff001; Aikaterini Valkanou aff001; Zoltan Kender aff001; Jan Pfeiffenberger aff004; Lars Kihm aff001; Thomas Fleming aff001; Peter Paul Nawroth aff001; Stefan Kopf aff001
Působiště autorů:
Department of Medicine I: Endocrinology and Clinical Chemistry, University Hospital Heidelberg, Heidelberg, Germany
aff001; Deutsches Zentrum für Diabetesforschung (DZD) e.V., Munich-Neuherberg, Germany
aff002; Medicover München Neuroendokrinologie, Munich, Germany
aff003; Department of Medicine IV: Gastroenterology and Hepatology, University Hospital Heidelberg, Heidelberg, Germany
aff004; Joint-IDC, Institute for Diabetes and Cancer at Helmholtz Zentrum Munich and University of Heidelberg, Munich-Neuherberg and Heidelberg, Germany
aff005
Vyšlo v časopise:
PLoS ONE 14(9)
Kategorie:
Research Article
doi:
https://doi.org/10.1371/journal.pone.0222771
Souhrn
Asprosin is a counter-regulatory hormone to insulin which plays a role in fasting. It may therefore also play a role in hypoglycaemia unawareness, which has been subsequently examined in this pilot study. Intravenous glucose tolerance test was used to induce controlled hyperglycemia whereas a hyperinsulinemic clamp test was used to induce a controlled hypoglycaemia in 15 patients with diabetes type 1, with and without hypoglycaemia unawareness. Changes in asprosin plasma levels did not differ between patients with and without hypoglycaemia unawareness. However, nine patients with insulin resistance as well as higher liver stiffness values and low-density lipoprotein but lower high-density lipoprotein levels did not show the expected increase in asprosin plasma levels during hypoglycemia. Therefore, insulin resistance and alterations in liver structure, most likely early stages of non-alcoholic fatty liver disease, seem to be relevant in type 1 diabetes and do not only lead to elevated plasma levels of asprosin, but also to a blunted asprosin response in hypoglycemia.
Klíčová slova:
Medicine and health sciences – Endocrinology – Endocrine disorders – Diabetic endocrinology – Insulin – Endocrine physiology – Metabolic disorders – Hypoglycemia – Blood sugar – Pharmacology – Drugs – Hypoglycemics – Biology and life sciences – Biochemistry – Hormones – Anatomy – Body fluids – Blood – Blood plasma – Physiology – Physical sciences – Chemistry – Chemical compounds – Organic compounds – Carbohydrates – Monosaccharides – Glucose – Organic chemistry
Zdroje
1. Romere C, Duerrschmid C, Bournat J, Constable P, Jain M, Xia F, et al. Asprosin, a Fasting-Induced Glucogenic Protein Hormone. Cell. 2016;165(3):566–79. Epub 2016/04/19. doi: 10.1016/j.cell.2016.02.063 27087445; PubMed Central PMCID: PMC4852710.
2. Duerrschmid C, He Y, Wang C, Li C, Bournat JC, Romere C, et al. Asprosin is a centrally acting orexigenic hormone. Nature medicine. 2017;23(12):1444–53. Epub 2017/11/07. doi: 10.1038/nm.4432 29106398; PubMed Central PMCID: PMC5720914.
3. Liang Q, Zhong L, Zhang J, Wang Y, Bornstein SR, Triggle CR, et al. FGF21 maintains glucose homeostasis by mediating the cross talk between liver and brain during prolonged fasting. Diabetes. 2014;63(12):4064–75. Epub 2014/07/16. doi: 10.2337/db14-0541 25024372.
4. Orchard TJ, Nathan DM, Zinman B, Cleary P, Brillon D, Backlund JY, et al. Association between 7 years of intensive treatment of type 1 diabetes and long-term mortality. Jama. 2015;313(1):45–53. Epub 2015/01/07. doi: 10.1001/jama.2014.16107 25562265; PubMed Central PMCID: PMC4306335.
5. Miller RG, Secrest AM, Sharma RK, Songer TJ, Orchard TJ. Improvements in the life expectancy of type 1 diabetes: the Pittsburgh Epidemiology of Diabetes Complications study cohort. Diabetes. 2012;61(11):2987–92. Epub 2012/08/02. doi: 10.2337/db11-1625 22851572; PubMed Central PMCID: PMC3478551.
6. Gubitosi-Klug RA, Braffett BH, White NH, Sherwin RS, Service FJ, Lachin JM, et al. Risk of Severe Hypoglycemia in Type 1 Diabetes Over 30 Years of Follow-up in the DCCT/EDIC Study. Diabetes care. 2017;40(8):1010–6. Epub 2017/05/28. doi: 10.2337/dc16-2723 28550194; PubMed Central PMCID: PMC5521975.
7. Novodvorsky P, Bernjak A, Chow E, Iqbal A, Sellors L, Williams S, et al. Diurnal Differences in Risk of Cardiac Arrhythmias During Spontaneous Hypoglycemia in Young People With Type 1 Diabetes. Diabetes care. 2017;40(5):655–62. Epub 2017/02/19. doi: 10.2337/dc16-2177 28213374.
8. Smith CB, Choudhary P, Pernet A, Hopkins D, Amiel SA. Hypoglycemia unawareness is associated with reduced adherence to therapeutic decisions in patients with type 1 diabetes: evidence from a clinical audit. Diabetes care. 2009;32(7):1196–8. Epub 2009/04/25. doi: 10.2337/dc08-2259 19389817; PubMed Central PMCID: PMC2699737.
9. Martin-Timon I, Del Canizo-Gomez FJ. Mechanisms of hypoglycemia unawareness and implications in diabetic patients. World journal of diabetes. 2015;6(7):912–26. Epub 2015/07/18. doi: 10.4239/wjd.v6.i7.912 26185599; PubMed Central PMCID: PMC4499525.
10. Young MJ, Boulton AJ, MacLeod AF, Williams DR, Sonksen PH. A multicentre study of the prevalence of diabetic peripheral neuropathy in the United Kingdom hospital clinic population. Diabetologia. 1993;36(2):150–4. Epub 1993/02/01. doi: 10.1007/bf00400697 8458529.
11. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, et al. A new equation to estimate glomerular filtration rate. Annals of internal medicine. 2009;150(9):604–12. Epub 2009/05/06. doi: 10.7326/0003-4819-150-9-200905050-00006 19414839; PubMed Central PMCID: PMC2763564.
12. Nowotny B, Zahiragic L, Bierwagen A, Kabisch S, Groener JB, Nowotny PJ, et al. Low-energy diets differing in fibre, red meat and coffee intake equally improve insulin sensitivity in type 2 diabetes: a randomised feasibility trial. Diabetologia. 2015;58(2):255–64. Epub 2014/11/27. doi: 10.1007/s00125-014-3457-8 25425219.
13. DeFronzo RA, Tobin JD, Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. The American journal of physiology. 1979;237(3):E214–23. Epub 1979/09/01. doi: 10.1152/ajpendo.1979.237.3.E214 382871.
14. Hompesch M, Rave K. An analysis of how to measure glucose during glucose clamps: are glucose meters ready for research? Journal of diabetes science and technology. 2008;2(5):896–8. Epub 2008/09/01. doi: 10.1177/193229680800200522 19885275; PubMed Central PMCID: PMC2769796.
15. Hahn RG, Ljunggren S, Larsen F, Nystrom T. A simple intravenous glucose tolerance test for assessment of insulin sensitivity. Theoretical biology & medical modelling. 2011;8:12. Epub 2011/05/04. doi: 10.1186/1742-4682-8-12 21535887; PubMed Central PMCID: PMC3113339.
16. Schauer IE, Snell-Bergeon JK, Bergman BC, Maahs DM, Kretowski A, Eckel RH, et al. Insulin resistance, defective insulin-mediated fatty acid suppression, and coronary artery calcification in subjects with and without type 1 diabetes: The CACTI study. Diabetes. 2011;60(1):306–14. Epub 2010/10/28. doi: 10.2337/db10-0328 20978091; PubMed Central PMCID: PMC3012187.
17. Wang Y, Qu H, Xiong X, Qiu Y, Liao Y, Chen Y, et al. Plasma Asprosin Concentrations Are Increased in Individuals with Glucose Dysregulation and Correlated with Insulin Resistance and First-Phase Insulin Secretion. Mediators of inflammation. 2018;2018:9471583. Epub 2018/05/11. doi: 10.1155/2018/9471583 29743813; PubMed Central PMCID: PMC5883982.
18. Sini M, Sorbello O, Civolani A, Liggi M, Demelia L. Non-invasive assessment of hepatic fibrosis in a series of patients with Wilson's Disease. Digestive and liver disease: official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver. 2012;44(6):487–91. Epub 2012/01/21. doi: 10.1016/j.dld.2011.12.010 22261353.
19. Sviklane L, Olmane E, Dzerve Z, Kupcs K, Pirags V, Sokolovska J. Fatty liver index and hepatic steatosis index for prediction of non-alcoholic fatty liver disease in type 1 diabetes. Journal of gastroenterology and hepatology. 2018;33(1):270–6. Epub 2017/05/04. doi: 10.1111/jgh.13814 28464337.
20. Toonen EJ, Mirea AM, Tack CJ, Stienstra R, Ballak DB, van Diepen JA, et al. Activation of proteinase 3 contributes to Non-alcoholic Fatty Liver Disease (NAFLD) and insulin resistance. Molecular medicine (Cambridge, Mass). 2016;22. Epub 2016/06/05. doi: 10.2119/molmed.2016.00033 27261776; PubMed Central PMCID: PMC5004724.
21. Adolph TE, Grander C, Grabherr F, Tilg H. Adipokines and Non-Alcoholic Fatty Liver Disease: Multiple Interactions. International journal of molecular sciences. 2017;18(8). Epub 2017/08/02. doi: 10.3390/ijms18081649 28758929; PubMed Central PMCID: PMC5578039.
22. Peng K, Mo Z, Tian G. Serum Lipid Abnormalities and Nonalcoholic Fatty Liver Disease in Adult Males. The American journal of the medical sciences. 2017;353(3):236–41. Epub 2017/03/07. doi: 10.1016/j.amjms.2017.01.002 28262209.
23. Rao RB, Khan SA, Suleman D, Ahmed I, Lakshmi GJ, Laxminarayana V. Study of Lipid Profile in Non-Alcoholic Fatty Liver Disease. IOSR Journal of Dental and Medical Sciences. 2017;16(11):46–9.
24. Zhang L, Chen C, Zhou N, Fu Y, Cheng X. Circulating asprosin concentrations are increased in type 2 diabetes mellitus and independently associated with fasting glucose and triglyceride. Clinica chimica acta; international journal of clinical chemistry. 2017. Epub 2017/11/07. doi: 10.1016/j.cca.2017.10.034 29104036.
Článek vyšel v časopise
PLOS One
2019 Číslo 9
- Tisícileté topoly, mokří psi, stárnoucí kočky a ospalé octomilky – „jednohubky“ z výzkumu 2024/41
- Jaké jsou aktuální trendy v léčbě karcinomu slinivky?
- Menstruační krev má značný diagnostický potenciál, mimo jiné u diabetu
- Proč jsou nemocnice nepřítelem spánku? A jak to změnit?
- Metamizol jako analgetikum první volby: kdy, pro koho, jak a proč?